Clinical Trials

We have three product candidates in clinical development.

  • Cobomarsen (MRG-106), an inhibitor (LNA antimiR®) of microRNA-155, is being developed for treatment of blood cancers;
  • MRG-201, a synthetic microRNA mimic (promiR) of microRNA-29b is being developed for treatment or prevention of pathologic fibrosis; and,
  • MRG-110 (S95010), a synthetic microRNA inhibitor (LNA antimiR®) of microRNA-92, is being developing in collaboration with Servier for treatment of ischemic conditions including heart failure.

Open clinical trials:

Cobomarsen (MRG-106) Anti-cancer Product Candidate

The Phase 1 clinical trial, MRG106-11-101, is designed to evaluate the safety and tolerability of the investigational drug, cobomarsen (MRG-106). Cobomarsen is a synthetic inhibitor (LNA antimiR®) of microRNA-155.  microRNA-155 plays a role in the proliferation and survival of malignant cancer cells in certain types of blood cancer. In laboratory tests inhibition of microRNA-155 in lymphoma cells reduces cancer cell proliferation. The Phase 1 trial of MRG-106 is being conducted in patients suffering from cutaneous T-cell lymphoma (CTCL) of the mycosis fungoides (MF) sub-type. In addition to assessments of safety and tolerability, the trial will also assess pharmacokinetics (how cobomarsen is processed by the body) and the effects of cobomarsen treatment on the cancerous skin lesions of MF patients. The Phase 1 clinical trial is also enrolling patients with chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and adult T-cell leukemia/lymphoma (ATLL) to study whether cobomarsen may inhibit the growth of these types of blood cancer.

MRG106-11-101 is ongoing and recruiting participants with CLL, DLBCL and ATLL.

Study of cobomarsen (MRG-106) at


MRG-110 (S95010) Ischemia Product Candidate

The Phase 1 trial, CL1-95010-001, sponsored by Servier, is designed to evaluate the safety, tolerability, and pharmacokinetics of MRG-110 in healthy human volunteers. In addition, blood samples from study participants will be tested to identify molecular changes in plasma or inside cells that may occur in response to MRG-110 treatment. These biomarkers of MRG-110 activity may support potential future clinical trials of MRG-110 in the treatment of heart failure or other ischemic conditions where blood flow into tissues is compromised.

CL1-95010-001 is ongoing and recruiting participants.

Study of intravenous administration of MRG-110 (S95010) at